Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 4/20 | 0.37 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.35 |
| ▸ | TTK | P33981 | 9/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25451152 | 0.94 | PTK6 (0.35) | PTK2PTK6TTKAURKB | |
| SCHEMBL25173554 | 0.94 | PTK2 (0.35) | PTK2PTK6TTKRETCNR2 | |
| SCHEMBL25451174 | 0.94 | TTK (0.39) | PTK2PTK6TTKAXL | |
| SCHEMBL24112096 | 0.93 | PTK6 (0.34) | PTK2PTK6TTKMAPKAPK5 | |
| SCHEMBL25451209 | 0.93 | PTK2 (0.37) | PTK2PTK6TTKAURKBRET | |
| SCHEMBL24112501 | 0.93 | PTK2 (0.34) | PTK2PTK6TTKAXL | |
| SCHEMBL30385676 | 0.92 | TTK (0.37) | PTK2PTK6TTKRETCNR2 | |
| SCHEMBL24112110 | 0.92 | TTK (0.37) | PTK2PTK6TTKRETCNR2 | |
| SCHEMBL25451145 | 0.92 | PTK2 (0.34) | PTK2PTK6TTK | |
| Iodide SCHEMBL25170443 | 0.92 | TTK (0.37) | PTK2PTK6TTKRETCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4161931-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2026-02-18 | — | — | EP | claimed |
| EP-4161931-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2026-02-18 | — | — | EP | disclosed |
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4161931-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2023-04-12 | — | — | EP | disclosed |
| WO-2021249896-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | IKZF3, RRP15, IK | PTK2 3799/4885PTK6 925/4885TTK 4336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.